Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure

Physiological Genomics

Volumn 2002, Issue 10, 2002, Pages 31-44

  Hwang, Juey Jen ^a,b   Allen, Paul D ^a   Tseng, George C ^c   Lam, Ching Wan ^a   Fananapazir, Lameh ^d   Dzau, Victor J ^a   Liew, Choong Chin ^a,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cDNA microarray; Normalization; Real time reverse transcription polymerase chain reaction

Indexed keywords

EID: 0345806493     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00122.2001     Document Type: Article

References (53)

1. Arthur GD and Beicastro AN. A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy. Mol Cell Biochem 176: 241-248, 1997.
2. 31P-NMR and surface fluorometry study. Basic Res Cardiol 85: 342-357, 1990.
3. Baba H, Ishiwata T, Takashi E, Xu G, and Asano G. Expression and localization of lumican in the ischemic and reperfused rat heart. Jpn Circ J 65: 445-450, 2001.
4. Barrans JD, Stamatiou D, and Liew CC. Construction of a human cardiovascular cDNA microarray: portrait of the failing heart. Biochem Biophys Res Commun 280: 964-969, 2001.
5. Benevolensky D, Belikova Y, Mohammadzadeh R, Trouve P, Marotte F, Russo-Marie F, Samuel JL, and Charlemagne D. Expression and localization of the annexins II, V, and VI in myocardium from patients with end-stage heart failure. Lab Invest 80: 123-133, 2000.
6. Bowles NE, Bowles KR, and Towbin JA. The "final common pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy. Herz 25: 168-175, 2000.
7. Corbett JM, Why HJ, Wheeler CH, Richardson PJ, Archard LC, Yacoub MH, and Dunn MJ. Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 19: 2031-2042, 1998.
8. D'Amico M, Di Filippo C, La M, Solito E, McLean PG, Flower RJ, Oliani SM, and Perretti M. Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J 14: 1867-1869, 2000.
9. Dempsey AA, Pabalan N, Tang HC, and Liew CC. Organization of human cardiovascular-expressed genes on chromosome 21 and 22. J Mol Cell Cardiol 33: 587-591, 2001.
10. Dempsey AA, Ton C, and Liew CC. A cardiovascular EST repertoire: progress and promise for understanding cardiovascular disease. Mol Med Today 6: 231-237, 2000.
11. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, and Trent JM. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14: 457-460, 1996.
12. Everett AD, Stoops TD, Nairn AC, and Brautigan D. Angiotensin II regulates phosphorylation of translation elongation factor-2 in cardiac myocytes. Am J Physiol Heart Circ Physiol 281: H161-H167, 2001.
13. Fananapazir L and Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation 92: 7000-7004, 1995.
14. Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA 281: 1746-1752, 1999.
15. Friddle CJ, Koga T, Rubin EM, and Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci USA 97: 6745-6750, 2000.
16. Gollob MH, Green MS, Tang A, Ahmad F, Hassan A, Gollob T, Lozado R, Gonzales O, Tapscott T, Karibe A, Fananapazir L, Bachinski L, and Roberts R. Identification of a gene responsible for Wolff-Parkinson-White Syndrome. N Engl J Med 344: 1823-1831, 2001.
17. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, and Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
18. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2: 811-820, 2000.
19. Hwang DM, Dempsey AA, Lee CY, and Liew CC. Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags. Genomics 66: 1-14, 2000.
20. Hwang DM, Dempsey AA, Wang RX, Rezvani M, Barrans JD, Dai KS, Wang HY, Ma H, Cukerman E, Liu YQ, Gu JR, Zhang JH, Tsui SKW, Waye MMY, Fung KP, Lee CY, and Liew CC. A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. Circulation 96: 4146-4203, 1997.
21. Hwang JJ, Dzau VJ, and Liew CC. Genomics and the pathophysiology of heart failure. Current Cardiol Rep 3: 198-207, 2001.
22. Ichida F, Tsubata S, Bowles KR, Haneda N, Uese K, Miyawaki T, Dreyer WJ, Messina J, Li H, Bowles NE, and Towbin JA. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103: 1256-1263, 2001.
23. Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, Kimura A, Kato H, and Imaizumi T. Expression of protooncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 83: 594-601, 1998.
24. Kim S, Ko J, Kim JH, Choi EC, and Na DS. Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: specific interaction model. FEBS Lett 489: 243-248, 2001.
25. Lee ML, Kuo FC, Whitmore GA, and Sklar J. Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. Proc Natl Acad Sci USA 97: 9834-9839, 2000.
26. Lim DS, Roberts R, and Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol 38: 1175-1180, 2001.
27. Liu TJ, Lai HC, Wu W, Chinn S, and Wang PH. Developing a strategy to define the effects of insulin-like growth factor-1 on gene expression profiles in cardiomyocytes. Circ Res 88: 1231-1238, 2001.
28. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, and Bild DE. Prevalence of hypertrophie cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 92: 785-789, 1995.
29. Miller RA, Galecki A, and Shmookler-Reis RJ. Interpretation, design, and analysis of gene array expression experiments. J Gerontol Biol Sci 56A: B52-B57, 2001.
30. Mills JC, Roth KA, Cagan RL, and Gordon JI. DNA microarrays and beyond: completing the journey from tissue to cell. Nat Cell Biol 3: E175-E178, 2001.
31. Molkentin JD and Dorn GW II. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63: 391-426, 2001.
32. Mujumdar VS and Tyagi SC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens 17: 261-270, 1999.
33. Murray KP, Mathure S, Kaul R, Khan S, Carson LF, Twiggs LB, Martens MG, and Kaul A. Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol 76: 176-182, 2000.
34. Olson TM, Doan TP, Kishimoto NY, Whitby FG, Ackerman MJ, and Fananapazir L. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol 32: 1687-1694, 2000.
35. Sato Y, Ferguson DG, Sako H, Dorn GW, Kadambi VJ, Yatani A, Hoit BD, Walsh RA, and Kranias EG. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem 273: 28470-28477, 1998.
36. Schaub MC and Hirzel HO. Atrial and ventricular isomyosin composition in patients with different forms of cardiac hypertrophy. Basic Res Cardiol 82, Suppl 2: 357-367, 1987.
37. Schena M, Shalon D, Davis RW, and Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470, 1995.
38. Schonberger J and Seidman CE. Many roads lead to a broken heart: the genetics of dilated cardiomyopathy. Am J Hum Genet 69: 249-260, 2001.
39. Seidman CE. Hypertrophic cardiomyopathy: from man to mouse. J Clin Invest 106: S9-S13, 2000.
40. Siwik DA, Tzortzis JD, Pimentai DR, Chang DL, Pagano PJ, Singh K, Sawyer DB, and Colucci WS. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 85: 147-153, 1999.
41. 2+-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation 104: 658-663, 2001.
42. Stanton LW, Garrard LJ, Damm D, Garrick BL, Lam A, Kapoun AM, Zheng Q, Protter AA, Schreiner GF, and White RT. Altered patterns of gene expression in response to myocardial infarction. Circ Res 86: 939-945, 2000.
43. Steuerwald N, Cohen J, Herrera RJ, and Brenner CA. Analysis of gene expression in single oocytes and embryos by real-time rapid cycle fluorescence monitored RT-PCR. Mol Hum Reprod 5: 1034-1039, 1999.
44. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, Price RL, Schaefer E, and Yager K. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 105: 875-886, 2000.
45. 2+-ATPase gene. Circ Res 71: 9-17, 1992.
46. Tseng GC, Oh MK, Rohlin L, Liao JC, and Wong WH. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res 29: 2549-2557, 2001.
47. Wang X, Osinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J, Hewett T, and Robbins J. Expression of R120G-αB-crystallin causes aberrant desmin and aB-crystallin aggregation and cardiomyopathy in mice. Circ Res 89: 3-5, 2001.
48. Wigle ED, Rakowski H, Kimball BP, and Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92: 1680-1692, 1995.
49. Wu TD. Analysing gene expression data from DNA microarrays to identify candidate genes. J Pathol 95: 53-65, 2001.
50. Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, Hawthorn L, Mitchell CA, Young JB, Francis GS, McCarthy PM, and Bond M. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102: 3046-3052, 2000.
51. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, and Speed TP. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: e15 (p. 1-10), 2002.
52. Yuan A, Yu CJ, Luh KT, Chen WJ, Lin FY, Kuo SH, and Yang PC. Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR. Lab Invest 80: 1671-1680, 2000.
53. Zhou ZQ and Hurlin PJ. The interplay between Mad and Myc in proliferation and differentiation. Trends Cell Biol 11: S10-S14, 2001.